Peripheral Arterial Disease Clinical Trial
Official title:
A Randomised Controlled Trial to Analyse the Histological, Physiological and Haemorrheological Adaptations to Supervised Exercise Training in Claudicants
NCT number | NCT01980602 |
Other study ID # | 11/YH/0210 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | September 24, 2013 |
Last updated | November 4, 2013 |
Start date | March 2011 |
Title: How does exercise improve the calf muscle in patients with poor blood supply to their
leg?
Purpose of the project: Patients with peripheral arterial disease have a poor blood supply
to their lower leg. The reduced inflow prevents the leg from utilising nutrients and oxygen
as easily as a healthy leg would. This causes pain when walking (intermittent claudication),
which often occurs after a reproducible distance e.g. every 50 yards. These patients have a
reduction in their quality of life as they feel embarrassed in social situations e.g.
walking around town requires multiple breaks, so they tend to avoid this and isolate
themselves more.
One treatment for claudication is exercising until the pain comes on; which most are
reluctant to do. Walking up to three times a week for an hour, can double most people's
walking distances, but doesn't always. The reason why some improve with exercise and others
do not remains unknown.
This project will be the first randomised controlled trial of exercise in claudicants that
focuses on the adaptations that occur in the muscle at a cellular level. We wish to compare
muscle cells from a group that have exercised and group that have not. We will focus on the
change in muscle cell size and function at present, and later progress to why and how this
happens.
Methods: We will take measurements at the start of the study (baseline), after 6 weeks and
then 3, 6 and 12 months. These measurements will be of a patient's fitness, actual walking
distances and blood samples. At the time of surgery, muscle from the calf will be taken from
the affected leg. This will be processed at the University's biomedical science department
to look at the different types of muscle fibre and how efficiently they are working.
Status | Recruiting |
Enrollment | 70 |
Est. completion date | |
Est. primary completion date | July 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 45 Years and older |
Eligibility |
Inclusion Criteria: - Community dwelling older adults aged 45 and over - Diagnosis of intermittent claudication - ABPI < 0.9 with symptoms in keeping with intermittent claudication - Undergoing surgery for claudication - Ability to walk without assistance - Healthy control patients who are undergoing varicose vein surgery Exclusion Criteria: - Participants who are unable to provide informed consent - Severe of acute cardiovascular, musculoskeletal or pulmonary illness - Critical limb ischaemia - Active treatment for cancer - Rheumatoid arthritis or any patient receiving steroids or disease modifying Antirheumatic drugs (DMARDS) - Failure to complete a CPET |
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Hull Royal Infirmary | Hull |
Lead Sponsor | Collaborator |
---|---|
University of Hull |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measurement of cardiovascular ability as recorded by their anaerobic threshold and peak VO2 after 6 weeks of exercise training or standard care | Patients will undergo cardiopulmonary exercise testing to assess whether a 6 week exercise programme improves the cardiovascular fitness | 6 weeks | No |
Secondary | Measure the changes in muscle fibre type with exercise training or standard care | Histological analysis to measure the percentage of different types of muscle fibres, and how these are affected by 6 weeks of exercise compared to standard treatment. | Baseline, 6 weeks, 3 months, 6 months, and 12 months | No |
Secondary | Measurement of endothelial function after a period or exercise therapy or standard care | To identify if 6 weeks of exercise improves the endothelial function. | Baseline, 6 weeks, 3 months, 6 months, and 12 months | No |
Secondary | Measurement of inflammatory markers with exercise treatment or standard care | To identify whether 6 weeks of exercise therapy improves inflammatory markers | Baseline, 6 weeks, 3 months, 6 months, and 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Completed |
NCT02022423 -
Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease
|
N/A |